Compare MTC & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTC | TVGN |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Blank Checks |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.8M | 63.9M |
| IPO Year | 2018 | N/A |
| Metric | MTC | TVGN |
|---|---|---|
| Price | $5.97 | $5.49 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.5K | ★ 403.0K |
| Earning Date | 12-13-2024 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.14 |
| 52 Week High | $6.05 | $10.76 |
| Indicator | MTC | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 70.42 | 65.91 |
| Support Level | $0.83 | $0.53 |
| Resistance Level | N/A | $10.76 |
| Average True Range (ATR) | 0.37 | 0.93 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 87.43 | 49.23 |
MMTEC Inc provides Internet-based technology services and solutions to the Chinese language speaking hedge funds, mutual funds, registered investment advisors, proprietary trading groups, and brokerage firms engaging in securities market transactions and settlements globally. It offers complete suite trading solutions, including services such as fund establishment, issuance, custody, transaction, and settlement. The Company currently has two operating segments, Gujia, MM Future, HC Securities, and MM Global. It generates maximum revenue from the Gujia segment. Gujia segment provides market data services and investor relations management services to customers in China.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.